Video

Dr. Norden on Differences Between mCODE and Cota's CNA Network

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.

Andrew Norden, MD, MPH, MBA, chief medical officer, Cota, discusses differences between mCODE and Cota’s CNA Network.

The mCODE initiative has been compared with Cota’s Cota nodal address (CNA) Network, but the 2 are not in competition because they serve different purposes, explains Norden. The CNA isolates homogeneous cohorts of patients in order to identify unnecessary variances in costs and outcomes. Conversely, mCODE provides a list of important data points that should be collected for patients with cancer so that further questions can be asked and addressed. These data points may come from providers, life science institutions, or payers. Everyone should have a vested interest in ensuring that these goals are met—especially Cota, says Norden.

Cota is especially supportive of the mCODE initiative and has engaged their initiative leaders to work collaboratively. If mCODE is widely adopted, one of the major advantages will be its applicability to medical record data points. This would make the ability to extract and analyze real-world data points significantly easier for the medical community, concludes Norden.

Related Videos
Viktor Grünwald, MD, PhD
Aaron Gerds, MD
Christine M. Lovly, MD, PhD, Ingram Associate Professor of Cancer Research, associate professor, medicine (hematology/oncology), Vanderbilt-Ingram Cancer Center
Haeseong Park, MD, MPH
David L. Porter, MD
Timothy Yap, MBBS, PhD, FRCP
Leo I. Gordon, MD, Abby and John Friend Professor of Oncology Research, professor, medicine (hematology and oncology), Feinberg School of Medicine, Robert H. Lurie Cancer Center
Hetty E. Carraway, MD, MBA, staff associate professor, Department of Medicine, School of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University; member, Immune Oncology Program, Case Comprehensive Cancer Center; vice chair, Strategy and Enterprise Development, Taussig Cancer Institute, Division of Hematologic Oncology and Blood Disorders, Cleveland Clinic
David A. Braun, MD, PhD, assistant professor, medicine (medical oncology), Louis Goodman and Alfred Gilman Yale Scholar, member, Center of Molecular and Cellular Oncology, Yale Cancer Center
Julia Foldi, MD, PhD